Pfizer Needs an Aspirin After Supreme Court Rejects Appeal

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

pfizer

The U.S. Supreme Court on Monday rejected an appeal from Pfizer Inc. (NYSE:PFE), leaving in place a $142 million settlement the pharmaceutical company must pay to the Kaiser Foundation on the grounds that Pfizer falsely marketed an epilepsy drug called Neurontin.

The Supreme Court is also allowing two other lawsuits on the same issue to continue forward, according to a report from Bloomberg. Pfizer allegedly marketed the drug as a treatment for migraines, manic-depressive issues, and neuropathic pain when it was not approved by the Food and Drug Administration for those uses.

Pfizer is also facing a nationwide class-action suit and a suit from insurer Aetna Inc. (NYSE:AET), both on the grounds that companies paid for dosages of the drug to treat conditions that the drug was not approved for. The parties suing Pfizer say that the company spent money marketing Neurontin as a treatment for a variety of disorders that it was not effective in treating. The company also misrepresented or attempted to hide trial data showing that the drug couldn’t treat those disorders, Bloomberg reports.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business